{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:55:13Z","timestamp":1761872113667,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.clml.2022.10.004","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T02:36:33Z","timestamp":1666838193000},"page":"e85-e96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of Patient Outcomes With Two Different Formulations of Melphalan as Conditioning Chemotherapy for Autologous Hematopoietic Cell Transplantation in Multiple Myeloma"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2166-2583","authenticated-orcid":false,"given":"Abdullah M.","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6861-3546","authenticated-orcid":false,"given":"Filiz","family":"Yucebay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuhong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira","family":"Umyarova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8676-7840","authenticated-orcid":false,"given":"Francesca","family":"Cottini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naresh","family":"Bumma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Rosko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don","family":"Benson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nidhi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Efebera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8838-1025","authenticated-orcid":false,"given":"Srinivas","family":"Devarakonda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.10.004_bib0001","first-page":"1","article-title":"Newly Diagnosed Myeloma in 2020","volume":"40","author":"Moreau","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annual Meeting"},{"issue":"2","key":"10.1016\/j.clml.2022.10.004_bib0002","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Fran\u00e7ais du My\u00e9lome","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2022.10.004_bib0003","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1080\/14656566.2017.1349102","article-title":"Melphalan hydrochloride for the treatment of multiple myeloma","volume":"18","author":"Esma","year":"2017","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"10.1016\/j.clml.2022.10.004_bib0004","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.bbmt.2012.08.011","article-title":"Fifty years of melphalan use in hematopoietic stem cell transplantation","volume":"19","author":"Bayraktar","year":"2013","journal-title":"Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.clml.2022.10.004_bib0005","first-page":"277","article-title":"Propylene glycol toxicity in children","volume":"19","author":"Lim","year":"2014","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.clml.2022.10.004_bib0006","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/0192623307310945","article-title":"Cyclodextrins","volume":"36","author":"Stella","year":"2008","journal-title":"Toxicol Pathol"},{"issue":"8","key":"10.1016\/j.clml.2022.10.004_bib0007","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/bmt.2014.120","article-title":"Phase IIa cross-over study of propylene glycol-free melphalan (LGD-353) and alkeran in multiple myeloma autologous transplantation","volume":"49","author":"Aljitawi","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.clml.2022.10.004_bib0008","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.bbmt.2015.08.026","article-title":"A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation","volume":"21","author":"Hari","year":"2015","journal-title":"Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.clml.2022.10.004_bib0009","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.bbmt.2018.04.028","article-title":"Pharmacokinetics of high-dose propylene glycol-free melphalan in multiple myeloma patients undergoing autologous hematopoietic cell transplantation","volume":"24","author":"Dhakal","year":"2018","journal-title":"Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.clml.2022.10.004_bib0010","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.clml.2022.10.004_bib0011","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.10.004_bib0012","doi-asserted-by":"crossref","unstructured":"Attal M, Lauwers-Cances V, Hulin C, et\u00a0al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. 2017; 376(14):1311-1320. doi: 10.1056\/NEJMoa1611750. PubMed PMID: 28379796.","DOI":"10.1056\/NEJMoa1611750"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2022.10.004_bib0013","article-title":"Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial","volume":"136","author":"Perrot","year":"2020","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.clml.2022.10.004_bib0014","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2022.10.004_bib0015","doi-asserted-by":"crossref","unstructured":"Stadtmauer EA, Pasquini MC, Blackwell B, et\u00a0al. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. 2019;37(7):589-597. doi: 10.1200\/jco.18.00685. PubMed PMID: 30653422.","DOI":"10.1200\/JCO.18.00685"},{"issue":"4","key":"10.1016\/j.clml.2022.10.004_bib0016","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41409-018-0302-6","article-title":"Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma","volume":"54","author":"Miller","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.clml.2022.10.004_bib0017","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.bbmt.2020.08.030","article-title":"Propylene Glycol-Free Melphalan versus PG-melphalan as conditioning for autologous hematopoietic cell transplantation for myeloma","volume":"26","author":"Monahan","year":"2020","journal-title":"Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2022.10.004_bib0018","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/bcp.12906","article-title":"High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation","volume":"82","author":"Nath","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.clml.2022.10.004_bib0019","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1365-2125.2010.03638.x","article-title":"Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy","volume":"69","author":"Nath","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clml.2022.10.004_bib0020","article-title":"Evaluating the incidence of engraftment syndrome with different melphalan formulations in adult multiple myeloma and immunoglobulin light chain amyloidosis patients undergoing autologous hematopoietic cell transplantation","author":"Kowalski","year":"2021","journal-title":"J Oncol Pharm Pract: Official publication of International Soc Oncology Pharm Pract"},{"issue":"7","key":"10.1016\/j.clml.2022.10.004_bib0021","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1177\/1078155218804042","article-title":"Evaluating the adverse effects of melphalan formulations","volume":"25","author":"Xiang","year":"2019","journal-title":"J Oncol Pharm Pract: Official publication of International Soc Oncology Pharm Pract"},{"key":"10.1016\/j.clml.2022.10.004_bib0022","doi-asserted-by":"crossref","unstructured":"Zar T, Graeber C, Perazella MA. Reviews: recognition, treatment, and prevention of propylene glycol toxicity. 2007; 20(3):217-219. doi: https:\/\/doi.org\/10.1111\/j.1525-139X.2007.00280.x.","DOI":"10.1111\/j.1525-139X.2007.00280.x"},{"issue":"10","key":"10.1016\/j.clml.2022.10.004_bib0023","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1080\/10837450.2016.1265557","article-title":"Solution stability of Captisol-stabilized melphalan (Evomela) versus Propylene glycol-based melphalan hydrochloride injection","volume":"23","author":"Singh","year":"2018","journal-title":"Pharm Dev Technol"},{"issue":"3","key":"10.1016\/j.clml.2022.10.004_bib0024","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1111\/bjh.17237","article-title":"Sex differences in outcomes in multiple myeloma","volume":"192","author":"Derman","year":"2021","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.clml.2022.10.004_bib0025","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/s41409-018-0388-x","article-title":"Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation","volume":"54","author":"Sidiqi","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.clml.2022.10.004_bib0026","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/s41409-018-0178-5","article-title":"Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective","volume":"53","author":"Badar","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.clml.2022.10.004_bib0027","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/j.bbmt.2016.08.026","article-title":"Phase II study of propylene glycol-free melphalan combined with carmustine, etoposide, and cytarabine for myeloablative conditioning in lymphoma patients undergoing autologous stem cell transplantation","volume":"22","author":"Cashen","year":"2016","journal-title":"Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022017104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022017104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:40:43Z","timestamp":1761871243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022017104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S2152265022017104"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.10.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Patient Outcomes With Two Different Formulations of Melphalan as Conditioning Chemotherapy for Autologous Hematopoietic Cell Transplantation in Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}